Literature DB >> 35291198

AIDS at 40th: The progress of HIV treatment in Japan.

Shinichi Oka1.   

Abstract

Forty years have passed since the first five AIDS cases in Los Angeles were reported in 1981. Looking back at the history, these 40 years could be divided into 3 phases. During the first 15 years, when there was little efficacious therapy against HIV, clinical research was directed to develop diagnosis and treatment for opportunistic infections, mainly Pneumocystis jirovecii pneumonia. When combination antiretroviral therapy (cART) became available in 1996, taking cART had been troublesome to most patients following 10 years because some of them had severe side effects, diet restrictions, high pill burdens, drug interactions, etc. It was not easy for patients to keep high adherence and, therefore, the virus easily obtained drug resistance. Although the prognosis has been dramatically improved, patients had been still living with hard times during the second phase. Along with advancement of anti-retroviral drugs that have allowed simple treatment possible, their life expectancy has further improved and is reaching almost nearly the general population in the following 15 years. However, some patients have recently faced an additional load to treat life-related comorbidities and non-AIDS defining malignancies. The problem is that these diseases start to occur in the 40s- or 50s-year-old generations and that means HIV-infected persons are suffering from pre-mature aging. AIDS no longer signifies death. However, we still have a lot to improve for their quality of life. 2022, National Center for Global Health and Medicine.

Entities:  

Keywords:  Pneumocystis jirovecii pneumonia; combination antiretroviral therapy; drug resistance; pre-mature aging; prevention; tailor-made therapy

Year:  2022        PMID: 35291198      PMCID: PMC8884036          DOI: 10.35772/ghm.2021.01120

Source DB:  PubMed          Journal:  Glob Health Med        ISSN: 2434-9186


  63 in total

Review 1.  HIV-1 drug resistance: can we overcome?

Authors:  Bluma G Brenner; Dan Turner; Mark A Wainberg
Journal:  Expert Opin Biol Ther       Date:  2002-10       Impact factor: 4.388

2.  Decay characteristics of HIV-1-infected compartments during combination therapy.

Authors:  A S Perelson; P Essunger; Y Cao; M Vesanen; A Hurley; K Saksela; M Markowitz; D D Ho
Journal:  Nature       Date:  1997-05-08       Impact factor: 49.962

3.  Outbreak of Pneumocystis jiroveci pneumonia in renal transplant recipients: P. jiroveci is contagious to the susceptible host.

Authors:  Hirohisa Yazaki; Norihiko Goto; Kazuharu Uchida; Takaaki Kobayashi; Hiroyuki Gatanaga; Shinichi Oka
Journal:  Transplantation       Date:  2009-08-15       Impact factor: 4.939

4.  Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity.

Authors:  G Moyle
Journal:  Clin Ther       Date:  2000-08       Impact factor: 3.393

5.  Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Updated Guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America.

Authors:  Henry Masur; John T Brooks; Constance A Benson; King K Holmes; Alice K Pau; Jonathan E Kaplan
Journal:  Clin Infect Dis       Date:  2014-02-27       Impact factor: 9.079

6.  Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.

Authors:  Kiyoto Tsuchiya; Hiroyuki Gatanaga; Natsuo Tachikawa; Katsuji Teruya; Yoshimi Kikuchi; Munehiro Yoshino; Takeshi Kuwahara; Takuma Shirasaka; Satoshi Kimura; Shinichi Oka
Journal:  Biochem Biophys Res Commun       Date:  2004-07-09       Impact factor: 3.575

7.  Detection of Pneumocystis carinii sequences by polymerase chain reaction: animal models and clinical application to noninvasive specimens.

Authors:  K Kitada; S Oka; S Kimura; K Shimada; T Serikawa; J Yamada; H Tsunoo; K Egawa; Y Nakamura
Journal:  J Clin Microbiol       Date:  1991-09       Impact factor: 5.948

8.  Class of antiretroviral drugs and the risk of myocardial infarction.

Authors:  Nina Friis-Møller; Peter Reiss; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa El-Sadr; Rodolphe Thiébaut; Stephane De Wit; Ole Kirk; Eric Fontas; Matthew G Law; Andrew Phillips; Jens D Lundgren
Journal:  N Engl J Med       Date:  2007-04-26       Impact factor: 91.245

9.  Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi.

Authors:  J C Edman; J A Kovacs; H Masur; D V Santi; H J Elwood; M L Sogin
Journal:  Nature       Date:  1988-08-11       Impact factor: 49.962

10.  Molecular evidence of interhuman transmission of Pneumocystis pneumonia among renal transplant recipients hospitalized with HIV-infected patients.

Authors:  Meja Rabodonirina; Philippe Vanhems; Sandrine Couray-Targe; René-Pierre Gillibert; Christell Ganne; Nathalie Nizard; Cyrille Colin; Jacques Fabry; Jean-Louis Touraine; Guy van Melle; Aimable Nahimana; Patrick Francioli; Philippe M Hauser
Journal:  Emerg Infect Dis       Date:  2004-10       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.